TYR and metastatic neoplasm: Based on the findings from the EU-RHAB study,13 our patient falls into the intermediate risk category at diagnosis (<1 yr + ATRT-TYR), although our patient had several high-risk factors like metastatic tumor, germline mutation, and omission of radiation at initial treatment.